Mumbai, April 1 -- Morepen Laboratorieshas received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for its Loratadine (anti-allergy API). This marks a significant milestone in Morepen's strategic entry into one of the world's largest pharmaceutical markets.

Published by HT Digital Content Services with permission from Capital Market....